{"gene":"GFAP","run_date":"2026-04-28T18:06:52","timeline":{"discoveries":[{"year":1996,"finding":"GFAP-null mice (generated by gene targeting in embryonic stem cells) showed severely reduced intermediate filaments in astrocytes and exhibited enhanced long-term potentiation (both population spike amplitude and EPSP slope) in the CA1 hippocampal region compared to controls, demonstrating that GFAP is required for normal astrocyte-neuronal interactions that modulate synaptic efficacy.","method":"Gene targeting (knockout mouse), electrophysiological recording of LTP in hippocampal slices","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular and physiological phenotype, well-controlled study","pmids":["8692820"],"is_preprint":false},{"year":1994,"finding":"S100 protein (a Ca2+-binding protein) binds directly to GFAP and inhibits its polymerization in a Ca2+-dependent manner: it interferes with nucleation and polymer growth, reduces the rate and extent of GFAP assembly, increases the critical concentration for assembly, and disassembles preformed glial filaments, suggesting S100 regulates glial filament dynamics in response to elevated intracellular Ca2+.","method":"Sedimentation assay, viscometry, in vitro polymerization assay","journal":"Biochimica et biophysica acta","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro assembly assay with quantitative kinetic analysis and stoichiometry","pmids":["7918670"],"is_preprint":false},{"year":2001,"finding":"Dominant missense mutations in the coding region of GFAP cause Alexander disease, establishing GFAP as the first identified gene whose primary mutation causes an astrocyte disorder; mutant GFAP leads to formation of Rosenthal fiber inclusions in astrocytes.","method":"DNA sequence analysis of patient samples, cellular transfection assays with mutant constructs","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple patient cohorts with sequence validation and functional transfection assays; independently replicated across multiple studies","pmids":["11138011"],"is_preprint":false},{"year":1998,"finding":"Transgenic mice overexpressing human GFAP develop astrocyte hypertrophy, upregulate small heat-shock proteins, and form cytoplasmic inclusion bodies (Rosenthal fibers) identical to those in Alexander disease, resulting in fatal encephalopathy; this established that elevated GFAP levels per se alter astrocyte function and cause pathology.","method":"Transgenic mouse overexpression, histological and immunohistochemical analysis","journal":"The American journal of pathology","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain-of-function with defined cellular and organismal phenotype; replicated in subsequent studies","pmids":["9466565"],"is_preprint":false},{"year":2009,"finding":"alphaB-crystallin (Cryab) regulates GFAP assembly and suppresses GFAP toxicity in Alexander disease mouse models: loss of Cryab increased mortality in GFAP-overexpressing mice, while transgenic elevation of Cryab rescued animals from terminal seizures, restored glutamate transporter Glt1 (EAAT2) expression, and reduced the CNS stress response, demonstrating an astrocyte-specific protective mechanism.","method":"Genetic crosses of mouse models (GFAP overexpressor × Cryab-null; AxD mutation knock-in × Cryab transgenic), survival analysis, immunohistochemistry, western blot","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 — epistasis via multiple genetic combinations with defined molecular and phenotypic readouts","pmids":["19129171"],"is_preprint":false},{"year":2021,"finding":"GFAP is palmitoylated in vitro and in vivo, with cysteine-291 identified as the unique palmitoylation site; PPT1 depalmitoylates GFAP. Hyperpalmitoylated GFAP promotes astrocyte proliferation, and in PPT1-deficient mice elevated palmitoylated GFAP accelerates astrogliosis. Mutation of Cys-291 to Ala attenuates astrogliosis and concurrent neurodegenerative pathology in PPT1-knockin mice.","method":"Palm-proteomics, in vitro palmitoylation assay, site-directed mutagenesis (C291A knock-in), cell proliferation assay, in vivo mouse model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro assay + site-specific mutagenesis + in vivo genetic rescue in the same study","pmids":["33753498"],"is_preprint":false},{"year":2016,"finding":"GFAPδ and GFAPα isoforms differ in their exchange dynamics within the intermediate filament network: FRAP experiments showed GFP-GFAPδ exchanges significantly more slowly than GFP-GFAPα; GFAPδ-induced network collapse further decreased recovery of both isoforms and altered cell morphology and focal adhesion size without affecting migration or proliferation.","method":"Fluorescence recovery after photobleaching (FRAP), live-cell imaging, focal adhesion analysis in astrocytoma cells","journal":"Cellular and molecular life sciences : CMLS","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization and dynamics experiment with functional consequence (focal adhesion size, morphology); single lab","pmids":["27141937"],"is_preprint":false},{"year":2014,"finding":"Isoform-specific silencing of GFAPα (canonical) in astrocytoma cells shifted the GFAPδ:GFAPα ratio, leading to changes in integrin expression, decreased plectin, increased laminin, and significantly decreased cell motility. Pan-GFAP knockdown caused decreased cell spreading, increased integrin expression, and >100-fold increased adhesion to laminin, demonstrating distinct isoform-specific roles of GFAP in regulating astrocyte–extracellular matrix interactions.","method":"shRNA-mediated isoform-specific knockdown, cell motility assay, adhesion assay, integrin and ECM protein analysis","journal":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","confidence":"Medium","confidence_rationale":"Tier 2 — isoform-specific KD with multiple orthogonal functional readouts; single lab","pmids":["24696300"],"is_preprint":false},{"year":2014,"finding":"Histone deacetylase (HDAC) inhibition (trichostatin A or sodium butyrate) reduced GFAP transcription in human astrocytes and astrocytoma cells, and the reduced transcription increased the GFAPδ:GFAPα ratio by promoting alternative splicing dependent on SR protein splicing factors; HDAC inhibition also caused GFAP network aggregation similar to GFAPδ-induced network collapse.","method":"HDAC inhibitor treatment, RT-qPCR, western blot, immunofluorescence, splicing factor analysis in primary human astrocytes and astrocytoma cells","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal methods linking histone acetylation to GFAP transcription, splicing, and network organization; single lab","pmids":["25128567"],"is_preprint":false},{"year":2018,"finding":"AxD patient-derived iPSC astrocytes carrying GFAP mutations (corrected by gene editing as isogenic controls) displayed GFAP aggregates, perinuclear redistribution of ER and lysosomes, impaired extracellular ATP release, and attenuated calcium wave propagation, demonstrating that AxD mutations in GFAP disrupt intracellular vesicle regulation and astrocyte secretory function.","method":"iPSC derivation from AxD patients, CRISPR/Cas9 isogenic correction, RNA-seq, organelle imaging, ATP release assay, calcium imaging","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — isogenic human iPSC model with multiple orthogonal functional and cell biological readouts","pmids":["30355500"],"is_preprint":false},{"year":2008,"finding":"Primary astrocytes from Alexander disease mouse models (GFAP overexpressor transgenic and AxD-mutation knock-in) showed that both mutant GFAP and excess wild-type GFAP promote cytoplasmic inclusion formation, disrupt the cytoskeleton, decrease cell proliferation, increase cell death, reduce proteasomal function, and compromise stress resistance.","method":"Primary astrocyte culture from transgenic and knock-in mice, immunocytochemistry, cell proliferation and death assays, proteasome activity assay","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — comparison of two genetic models with multiple functional readouts; single lab","pmids":["19146851"],"is_preprint":false},{"year":2008,"finding":"Glutamate activates the GFAP gene promoter in cortical astrocytes via metabotropic glutamate receptors (blocked by mGluR2/3 antagonist MCPG) and is mediated by TGF-β1 secretion, leading to Smad-2 nuclear translocation and requiring cooperative activation of both MAPK/ERK and PI3K pathways alongside the canonical TGF-β/Smad pathway.","method":"Transgenic GFAP-lacZ reporter astrocytes, neutralizing antibodies, pharmacological inhibitors (MCPG, PD98059, LY294002), Smad nuclear translocation assay","journal":"Journal of neurochemistry","confidence":"Medium","confidence_rationale":"Tier 2 — multiple pathway inhibitors and reporter assay in primary cells; single lab","pmids":["18419760"],"is_preprint":false},{"year":2005,"finding":"Mutant GFAP behavior in cellular transfection assays confirmed that pathogenic Alexander disease mutations produce a gain-of-function leading to Rosenthal fiber formation, and expanded the catalog of causative mutations across infantile, juvenile, and adult forms of the disease.","method":"DNA sequencing of patient cohorts, cellular transfection assays","journal":"Annals of neurology","confidence":"High","confidence_rationale":"Tier 2 — large multi-center cohort with functional transfection validation; replicated across forms of disease","pmids":["15732097"],"is_preprint":false},{"year":2000,"finding":"TNF-α treatment of cultured astrocytes caused dramatic GFAP over-expression associated with substantial activation of MAPK Erk2; this over-expression was significantly attenuated by the MAPK inhibitor PD98059, placing TNF-α–MAPK signaling upstream of GFAP upregulation.","method":"Astrocyte cell culture, western blot, pharmacological MAPK inhibition (PD98059)","journal":"Neuroreport","confidence":"Low","confidence_rationale":"Tier 3 — single lab, pharmacological inhibition without genetic confirmation","pmids":["10674496"],"is_preprint":false},{"year":1998,"finding":"TGF-β1 significantly increased GFAP mRNA and protein in cultured astrocytes without morphological change, while FGF-2 (acting through tyrosine kinase/FGFR autophosphorylation, blocked by 5′-methylthioadenosine) decreased GFAP mRNA and protein and also inhibited TGF-β1-mediated GFAP induction; cycloheximide blocked FGF-2 inhibition of TGF-β1-mediated GFAP mRNA increase only when both were applied together, indicating a protein-synthesis-dependent counter-regulatory mechanism.","method":"Astrocyte culture, northern blot, western blot, pharmacological inhibition, cycloheximide chase","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 — multiple growth factors, pharmacological dissection of receptor kinase involvement, protein synthesis requirement tested orthogonally","pmids":["9537840"],"is_preprint":false},{"year":2013,"finding":"Alternative splicing of GFAP generates isoforms (GFAPα and GFAPδ) with distinct subcellular mRNA localization: a larger fraction of GFAPα mRNA localizes to astrocyte protrusions compared to GFAPδ mRNA, and this differential localization depends on the distinct 3′-exon sequences of each isoform.","method":"RT-qPCR, immunofluorescence, subcellular mRNA fractionation, fluorescence in situ hybridization in primary mouse astrocytes","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 — direct mRNA localization experiment with 3′-exon-swapping evidence; single lab","pmids":["23991052"],"is_preprint":false},{"year":2013,"finding":"MeCP2 binds to methylated regions of the GFAP promoter and suppresses GFAP expression; transient siRNA knockdown of MeCP2 in the neonatal rat amygdala and hypothalamus increased GFAP mRNA and protein specifically in females but not males, without altering other astrocyte markers (S100β, vimentin), demonstrating sex-specific epigenetic regulation of GFAP by MeCP2.","method":"In vivo siRNA knockdown, RT-qPCR, western blot, immunohistochemistry in rat brain","journal":"Brain research","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo KD with region-specific and sex-specific specificity controls; single lab","pmids":["24269336"],"is_preprint":false},{"year":2018,"finding":"Maternal hypothyroidism causes epigenetic silencing of Gfap in developing neocortex via increased DNA methylation and decreased histone acetylation at the Gfap promoter, coupled with increased HDAC activity; thyroid hormone supplementation reversed these changes, demonstrating that thyroid hormone regulates GFAP transcription through coordinated DNA methylation and histone modification.","method":"Rat model of maternal hypothyroidism, bisulfite sequencing, ChIP for histone acetylation, HDAC activity assay, RT-qPCR, western blot","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — multiple epigenetic methods in vivo with rescue by hormone supplementation; single lab","pmids":["29852171"],"is_preprint":false},{"year":2013,"finding":"Transgenic analysis identified NFI, SP1, STAT3, and NF-κB binding sites within the human GFAP promoter as important regulators of promoter strength and/or astrocyte specificity, while mutation of a conserved AP-1 site had little effect; mutation of the B region (bp -1612 to -1489) spanning four contiguous sequences cooperatively reduced transgene activity by ≥50% each, indicating that multiple sites contribute cooperatively to GFAP transcriptional regulation.","method":"Transgenic mice carrying block-mutant and site-specific mutant GFAP-reporter constructs, in vivo reporter expression analysis","journal":"Glia","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo transgenic dissection of promoter elements with multiple mutations tested; single lab","pmids":["23832770"],"is_preprint":false},{"year":2019,"finding":"GFAP-null/Vimentin-null (GFAP−/−Vim−/−) double-knockout mice showed more pronounced memory extinction compared to wild-type in IntelliCage reversal learning tasks, while overall locomotion, learning in Morris water maze, and trace fear conditioning were comparable, indicating that the astrocyte intermediate filament system (GFAP + vimentin together) modulates hippocampal circuit reorganization underlying memory extinction.","method":"Double-knockout mice, open field, object recognition, Morris water maze, trace fear conditioning, IntelliCage reversal learning","journal":"Biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO with specific behavioral phenotype; however phenotype is specific to combined GFAP/vimentin loss","pmids":["31063456"],"is_preprint":false}],"current_model":"GFAP is the principal type III intermediate filament protein of mature astrocytes, functioning as the structural backbone of the astrocyte cytoskeleton; its polymerization is regulated by Ca²⁺-dependent S100 protein binding and by post-translational palmitoylation at Cys-291 (reversed by PPT1); transcription is controlled by a cooperative promoter network involving STAT3, NFI, SP1, and NF-κB, as well as by epigenetic mechanisms (DNA methylation, histone acetylation/MeCP2), and by TGF-β1/Smad–MAPK/PI3K signaling downstream of glutamate and TGF-β1; GFAP is required for normal astrocyte–neuron interactions that constrain hippocampal LTP, and dominant missense mutations or excess GFAP cause Alexander disease through protein aggregation (Rosenthal fibers), impaired vesicle trafficking and ATP secretion, disrupted organelle distribution, and reduced proteasomal function, a pathological cascade that is suppressed by alphaB-crystallin acting in an astrocyte-specific manner."},"narrative":{"teleology":[{"year":1994,"claim":"Establishing the first direct mechanism regulating GFAP filament dynamics: S100 protein was shown to inhibit GFAP polymerization in a Ca²⁺-dependent manner, identifying an assembly checkpoint responsive to intracellular calcium.","evidence":"In vitro sedimentation and viscometry polymerization assays with purified proteins","pmids":["7918670"],"confidence":"High","gaps":["Identity of the specific S100 family member(s) acting in vivo not resolved","Whether other intermediate filament-associated proteins compete with S100 for GFAP binding is unknown"]},{"year":1996,"claim":"GFAP was shown to be required for normal astrocyte–neuron communication: GFAP-null mice had severely reduced astrocyte intermediate filaments and enhanced hippocampal LTP, demonstrating that GFAP constrains synaptic plasticity.","evidence":"Gene-targeted knockout mouse with electrophysiological recording in hippocampal slices","pmids":["8692820"],"confidence":"High","gaps":["Mechanism by which GFAP loss enhances LTP (gliotransmitter release, K⁺ buffering, structural support) was not determined","Whether other intermediate filaments (vimentin) partially compensate was not addressed"]},{"year":1998,"claim":"Excess wild-type GFAP was shown to be sufficient to cause astrocyte pathology: transgenic GFAP-overexpressing mice formed Rosenthal fiber inclusions identical to those in Alexander disease and developed fatal encephalopathy, establishing a dose-dependent gain-of-function mechanism.","evidence":"Transgenic mouse overexpression with histological and immunohistochemical analysis","pmids":["9466565"],"confidence":"High","gaps":["Threshold of GFAP overexpression required to trigger pathology not quantified","Whether Rosenthal fibers are directly toxic or markers of a broader proteostatic failure was unresolved"]},{"year":1998,"claim":"TGF-β1 was identified as a key transcriptional inducer of GFAP, counteracted by FGF-2 through tyrosine kinase signaling in a protein-synthesis-dependent manner, establishing growth factor cross-talk in GFAP regulation.","evidence":"Astrocyte culture with northern/western blot, pharmacological inhibition, cycloheximide chase","pmids":["9537840"],"confidence":"Medium","gaps":["Identity of the protein whose new synthesis is required for FGF-2-mediated repression was not established","Whether this cross-talk operates in vivo during injury responses is untested"]},{"year":2001,"claim":"Dominant missense mutations in GFAP were identified as the cause of Alexander disease — the first Mendelian astrocyte disorder traced to a single gene — directly linking GFAP sequence variants to Rosenthal fiber formation.","evidence":"DNA sequencing of patient cohorts with cellular transfection validation","pmids":["11138011"],"confidence":"High","gaps":["How individual mutations alter GFAP filament assembly at the structural level was not resolved","Genotype–phenotype correlations for severity and onset age were incomplete"]},{"year":2005,"claim":"Expansion of the Alexander disease mutation catalog across infantile, juvenile, and adult forms confirmed a consistent gain-of-function mechanism for all pathogenic GFAP variants.","evidence":"Multi-center patient cohort sequencing with cellular transfection assays","pmids":["15732097"],"confidence":"High","gaps":["Whether different mutations activate distinct downstream stress pathways was not addressed"]},{"year":2008,"claim":"The signaling cascade upstream of GFAP transcriptional induction was elaborated: glutamate activates the GFAP promoter through mGluR2/3-mediated TGF-β1 secretion, Smad-2 nuclear translocation, and cooperative MAPK/ERK and PI3K pathway engagement.","evidence":"GFAP-lacZ reporter astrocytes with neutralizing antibodies and pathway-specific pharmacological inhibitors","pmids":["18419760"],"confidence":"Medium","gaps":["Whether Smad and MAPK/PI3K signals converge on the same promoter elements or act on distinct cis-elements not determined","Contribution of this pathway relative to other injury signals in vivo is unknown"]},{"year":2008,"claim":"Both excess wild-type and mutant GFAP were shown to impair proteasomal function and decrease cell proliferation in primary astrocytes, identifying proteostatic collapse as a central feature of GFAP toxicity in Alexander disease.","evidence":"Primary astrocyte cultures from transgenic and knock-in AxD mouse models with proteasome activity and cell death assays","pmids":["19146851"],"confidence":"Medium","gaps":["Whether proteasome impairment is a direct effect of GFAP aggregates or secondary to sequestration of proteasome regulators is unclear","Relative contribution of impaired autophagy vs. proteasome dysfunction not dissected"]},{"year":2009,"claim":"alphaB-crystallin was established as an astrocyte-specific suppressor of GFAP toxicity: its genetic elevation rescued AxD mouse models from seizures and restored glutamate transporter expression, while its loss exacerbated mortality.","evidence":"Epistatic genetic crosses (GFAP-overexpressor × Cryab-null; AxD knock-in × Cryab-transgenic) with survival, IHC, and western blot","pmids":["19129171"],"confidence":"High","gaps":["Mechanism of Cryab action (direct chaperone activity on GFAP filaments vs. aggregate clearance) not resolved","Whether Cryab restoration is therapeutically viable in humans is untested"]},{"year":2013,"claim":"Cooperative transcription factor architecture of the GFAP promoter was mapped in vivo: NFI, SP1, STAT3, and NF-κB sites each contribute to promoter strength and astrocyte specificity, with a cooperative B-region spanning four contiguous elements.","evidence":"Transgenic mice with block-mutant and site-specific mutant GFAP-reporter constructs","pmids":["23832770"],"confidence":"Medium","gaps":["Which factor combinations are essential versus modulatory in different brain regions is not resolved","Chromatin context and 3D promoter architecture were not examined"]},{"year":2013,"claim":"Epigenetic regulation of GFAP was demonstrated through MeCP2 binding to the methylated GFAP promoter; MeCP2 knockdown in vivo increased GFAP expression in a sex-specific manner, revealing a layer of epigenetic control.","evidence":"In vivo siRNA knockdown in neonatal rat amygdala and hypothalamus with RT-qPCR and western blot","pmids":["24269336"],"confidence":"Medium","gaps":["Molecular basis of the sex-specific effect is unknown","Relationship to MeCP2 loss in Rett syndrome pathology not explored"]},{"year":2014,"claim":"GFAP isoforms (α and δ) were shown to exert distinct functions: GFAP-α knockdown altered integrin expression and cell motility, while pan-GFAP knockdown drastically increased laminin adhesion, demonstrating isoform-specific regulation of astrocyte–ECM interactions.","evidence":"shRNA-mediated isoform-specific knockdown with motility, adhesion, integrin, and ECM protein analysis in astrocytoma cells","pmids":["24696300"],"confidence":"Medium","gaps":["Whether these isoform-specific ECM effects operate in primary astrocytes and in vivo is untested","Direct binding partners that distinguish the isoforms at the ECM interface are unknown"]},{"year":2016,"claim":"FRAP experiments revealed that GFAPδ exchanges more slowly than GFAPα within the filament network and that GFAPδ-induced network collapse alters focal adhesion size, linking isoform dynamics to cytoskeletal mechanotransduction.","evidence":"Fluorescence recovery after photobleaching and focal adhesion analysis in astrocytoma cells","pmids":["27141937"],"confidence":"Medium","gaps":["Whether altered exchange kinetics are due to intrinsic assembly differences or differential partner interactions is unclear","Relevance of GFAPδ network collapse to in vivo astrocyte morphology not established"]},{"year":2018,"claim":"Alexander disease mutations in GFAP were shown in a human iPSC model to disrupt organelle distribution (ER and lysosomes perinuclear redistribution), impair ATP secretion, and attenuate calcium wave propagation, identifying vesicle trafficking and secretory function as primary cellular deficits.","evidence":"Patient-derived iPSC astrocytes with CRISPR/Cas9 isogenic correction, organelle imaging, ATP release assay, calcium imaging","pmids":["30355500"],"confidence":"High","gaps":["Whether organelle redistribution is a direct mechanical consequence of GFAP aggregation or mediated by motor protein dysfunction is unknown","Contribution of impaired ATP release to non-cell-autonomous neuronal damage not quantified"]},{"year":2018,"claim":"Thyroid hormone was shown to regulate GFAP expression through coordinated DNA methylation and histone acetylation at the GFAP promoter, with maternal hypothyroidism causing epigenetic silencing reversible by hormone supplementation.","evidence":"Rat hypothyroidism model with bisulfite sequencing, ChIP, HDAC activity assay, and hormone rescue","pmids":["29852171"],"confidence":"Medium","gaps":["Which DNA methyltransferases and HDACs are directly recruited to the GFAP promoter in this context is not identified","Whether this contributes to neurodevelopmental deficits of congenital hypothyroidism is speculative"]},{"year":2021,"claim":"Palmitoylation at Cys-291 was identified as a post-translational modification that regulates GFAP function: hyperpalmitoylation (as in PPT1 deficiency) promotes astrocyte proliferation and gliosis, while a C291A knock-in attenuates neurodegeneration, revealing a lipid modification switch on GFAP.","evidence":"Palm-proteomics, in vitro palmitoylation assay, C291A knock-in mouse, cell proliferation assay","pmids":["33753498"],"confidence":"High","gaps":["The palmitoltransferase(s) that modify Cys-291 are not identified","How palmitoylation alters GFAP filament assembly or protein–protein interactions at the molecular level is unknown"]},{"year":null,"claim":"Key open questions remain: the structural basis by which individual Alexander disease mutations alter GFAP assembly, the identity of the palmitoltransferase modifying Cys-291, the mechanism linking GFAP aggregation to organelle redistribution and proteasome impairment, and whether alphaB-crystallin-based strategies can be translated therapeutically.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structural model of pathogenic GFAP filament assembly exists","Causal chain from GFAP aggregation to proteasome impairment versus autophagy dysfunction not dissected","Therapeutic window for Cryab or depalmitoylation strategies in Alexander disease unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,1,6]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[6,7]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,1,6,7]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,10]}],"pathway":[{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[0,7,19]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,13,14]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[2,3,9,10,12]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[0,19]}],"complexes":[],"partners":["CRYAB","S100B","PPT1","VIM"],"other_free_text":[]},"mechanistic_narrative":"GFAP is the principal type III intermediate filament protein of astrocytes, serving as the structural backbone of the astrocyte cytoskeleton and a critical regulator of astrocyte–neuron interactions, cell morphology, and extracellular matrix adhesion. Its polymerization is directly inhibited by Ca²⁺-dependent S100 protein binding and modulated by alphaB-crystallin, while palmitoylation at Cys-291 (reversed by PPT1) regulates astrocyte proliferation and gliosis [PMID:7918670, PMID:19129171, PMID:33753498]. Transcription of GFAP is controlled by cooperative promoter elements (NFI, SP1, STAT3, NF-κB) and epigenetic mechanisms including DNA methylation, histone acetylation, and MeCP2 binding, and is induced by TGF-β1/Smad–MAPK/PI3K signaling downstream of glutamate [PMID:23832770, PMID:18419760, PMID:24269336, PMID:29852171]. Dominant missense mutations in GFAP cause Alexander disease through protein aggregation into Rosenthal fibers, impaired vesicle trafficking and ATP secretion, disrupted organelle distribution, and reduced proteasomal function [PMID:11138011, PMID:30355500, PMID:19146851]."},"prefetch_data":{"uniprot":{"accession":"P14136","full_name":"Glial fibrillary acidic protein","aliases":[],"length_aa":432,"mass_kda":49.9,"function":"GFAP, a class-III intermediate filament, is a cell-specific marker that, during the development of the central nervous system, distinguishes astrocytes from other glial cells","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P14136/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/GFAP","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/GFAP","total_profiled":1310},"omim":[{"mim_id":"621283","title":"COILED-COIL DOMAIN-CONTAINING PROTEIN 85C; CCDC85C","url":"https://www.omim.org/entry/621283"},{"mim_id":"620461","title":"ENCEPHALITIS, ACUTE, INFECTION-INDUCED, SUSCEPTIBILITY TO, 12; IIAE12","url":"https://www.omim.org/entry/620461"},{"mim_id":"620315","title":"LEUKOENCEPHALOPATHY WITH VANISHING WHITE MATTER 5; VWM5","url":"https://www.omim.org/entry/620315"},{"mim_id":"618037","title":"ZINC FINGER PROTEIN 536; ZNF536","url":"https://www.omim.org/entry/618037"},{"mim_id":"617894","title":"TRANSMEMBRANE PROTEIN 50B; TMEM50B","url":"https://www.omim.org/entry/617894"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Intermediate filaments","reliability":"Supported"}],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":15929.3}],"url":"https://www.proteinatlas.org/search/GFAP"},"hgnc":{"alias_symbol":["FLJ45472"],"prev_symbol":[]},"alphafold":{"accession":"P14136","domains":[{"cath_id":"-","chopping":"133-218_233-337","consensus_level":"medium","plddt":93.9655,"start":133,"end":337}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P14136","model_url":"https://alphafold.ebi.ac.uk/files/AF-P14136-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P14136-F1-predicted_aligned_error_v6.png","plddt_mean":80.0},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=GFAP","jax_strain_url":"https://www.jax.org/strain/search?query=GFAP"},"sequence":{"accession":"P14136","fasta_url":"https://rest.uniprot.org/uniprotkb/P14136.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P14136/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P14136"}},"corpus_meta":[{"pmid":"21219963","id":"PMC_21219963","title":"GFAP in health and disease.","date":"2011","source":"Progress in neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/21219963","citation_count":844,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7952264","id":"PMC_7952264","title":"GFAP and astrogliosis.","date":"1994","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/7952264","citation_count":735,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25726916","id":"PMC_25726916","title":"Glial fibrillary acidic protein (GFAP) and the astrocyte intermediate filament system in diseases of the central nervous system.","date":"2015","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/25726916","citation_count":685,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2409105","id":"PMC_2409105","title":"Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes.","date":"1985","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/2409105","citation_count":673,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8120611","id":"PMC_8120611","title":"GFAP promoter directs astrocyte-specific expression in transgenic mice.","date":"1994","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/8120611","citation_count":430,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8247224","id":"PMC_8247224","title":"GFAP mRNA increases with age in rat and human brain.","date":"1993","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/8247224","citation_count":346,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18240313","id":"PMC_18240313","title":"GFAP promoter elements required for region-specific and astrocyte-specific expression.","date":"2008","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/18240313","citation_count":315,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16765104","id":"PMC_16765104","title":"GFAP transgenic zebrafish.","date":"2006","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/16765104","citation_count":302,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8692820","id":"PMC_8692820","title":"Targeted deletion in astrocyte intermediate filament (Gfap) alters neuronal physiology.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8692820","citation_count":280,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16314487","id":"PMC_16314487","title":"LIF and BMP signaling generate separate and discrete types of GFAP-expressing cells.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16314487","citation_count":223,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34572572","id":"PMC_34572572","title":"Beyond the GFAP-Astrocyte Protein Markers in the Brain.","date":"2021","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/34572572","citation_count":212,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9466565","id":"PMC_9466565","title":"Fatal encephalopathy with astrocyte inclusions in GFAP transgenic mice.","date":"1998","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/9466565","citation_count":209,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21917775","id":"PMC_21917775","title":"GFAP mutations, age at onset, and clinical subtypes in Alexander disease.","date":"2011","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21917775","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24749759","id":"PMC_24749759","title":"Enteric GFAP expression and phosphorylation in Parkinson's disease.","date":"2014","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/24749759","citation_count":152,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10412574","id":"PMC_10412574","title":"Glial fibrillary acidic protein (GFAP): modulation by growth factors and its implication in astrocyte differentiation.","date":"1999","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/10412574","citation_count":152,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7952266","id":"PMC_7952266","title":"Structure and transcriptional regulation of the GFAP gene.","date":"1994","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/7952266","citation_count":138,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30991306","id":"PMC_30991306","title":"Clinical characteristics of autoimmune GFAP astrocytopathy.","date":"2019","source":"Journal of neuroimmunology","url":"https://pubmed.ncbi.nlm.nih.gov/30991306","citation_count":132,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12928288","id":"PMC_12928288","title":"Differential expression of GFAP in early v late AMD: a quantitative analysis.","date":"2003","source":"The British journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/12928288","citation_count":128,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29196434","id":"PMC_29196434","title":"Type III Intermediate Filaments Desmin, Glial Fibrillary Acidic Protein (GFAP), Vimentin, and Peripherin.","date":"2017","source":"Cold Spring Harbor perspectives in biology","url":"https://pubmed.ncbi.nlm.nih.gov/29196434","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35252538","id":"PMC_35252538","title":"Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology.","date":"2022","source":"Alzheimer's & dementia (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/35252538","citation_count":102,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15662842","id":"PMC_15662842","title":"Expression specificity of GFAP transgenes.","date":"2004","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/15662842","citation_count":101,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35656116","id":"PMC_35656116","title":"Blocking C3d+/GFAP+ A1 Astrocyte Conversion with Semaglutide Attenuates Blood-Brain Barrier Disruption in Mice after Ischemic Stroke.","date":"2022","source":"Aging and disease","url":"https://pubmed.ncbi.nlm.nih.gov/35656116","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35002283","id":"PMC_35002283","title":"Glial Fibrillary Acidic Protein (GFAP): Neuroinflammation Biomarker in Acute Ischemic Stroke.","date":"2021","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/35002283","citation_count":95,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32811163","id":"PMC_32811163","title":"GFAP at 50.","date":"2020","source":"ASN neuro","url":"https://pubmed.ncbi.nlm.nih.gov/32811163","citation_count":94,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33601918","id":"PMC_33601918","title":"Regulation of GFAP Expression.","date":"2021","source":"ASN neuro","url":"https://pubmed.ncbi.nlm.nih.gov/33601918","citation_count":93,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27074724","id":"PMC_27074724","title":"Assessment of Serum UCH-L1 and GFAP in Acute Stroke Patients.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27074724","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9537840","id":"PMC_9537840","title":"Regulation of astrocyte GFAP expression by TGF-beta1 and FGF-2.","date":"1998","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/9537840","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15331155","id":"PMC_15331155","title":"Non-invasive imaging of GFAP expression after neuronal damage in mice.","date":"2004","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/15331155","citation_count":91,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19129171","id":"PMC_19129171","title":"Suppression of GFAP toxicity by alphaB-crystallin in mouse models of Alexander disease.","date":"2009","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/19129171","citation_count":88,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2664580","id":"PMC_2664580","title":"Two brain nuclei controlling circadian rhythms are identified by GFAP immunoreactivity in hamsters and rats.","date":"1989","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/2664580","citation_count":86,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32804092","id":"PMC_32804092","title":"Serum Glial Fibrillary Acidic Protein (GFAP) Is a Marker of Disease Severity in Frontotemporal Lobar Degeneration.","date":"2020","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/32804092","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9591779","id":"PMC_9591779","title":"Correlation of B-FABP and GFAP expression in malignant glioma.","date":"1998","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/9591779","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"6543600","id":"PMC_6543600","title":"Glial fibrillary acidic protein (GFAP) immunoreactivity in peripheral nerve sheath tumors.","date":"1984","source":"Ultrastructural pathology","url":"https://pubmed.ncbi.nlm.nih.gov/6543600","citation_count":70,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35204724","id":"PMC_35204724","title":"Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis.","date":"2022","source":"Biomolecules","url":"https://pubmed.ncbi.nlm.nih.gov/35204724","citation_count":67,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30667110","id":"PMC_30667110","title":"Importance of GFAP isoform-specific analyses in astrocytoma.","date":"2019","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/30667110","citation_count":66,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10384875","id":"PMC_10384875","title":"Neurons induce GFAP gene promoter of cultured astrocytes from transgenic mice.","date":"1999","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/10384875","citation_count":63,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30951262","id":"PMC_30951262","title":"Enteric Glia: S100, GFAP, and Beyond.","date":"2019","source":"Anatomical record (Hoboken, N.J. : 2007)","url":"https://pubmed.ncbi.nlm.nih.gov/30951262","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3897466","id":"PMC_3897466","title":"Measurement of GFAP in hepatic encephalopathy by ELISA and transblots.","date":"1985","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/3897466","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8954847","id":"PMC_8954847","title":"GFAP Transgenic Mice.","date":"1996","source":"Methods (San Diego, Calif.)","url":"https://pubmed.ncbi.nlm.nih.gov/8954847","citation_count":61,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8738264","id":"PMC_8738264","title":"Repeated seizures increase GFAP and vimentin in the hippocampus.","date":"1996","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/8738264","citation_count":60,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"15634232","id":"PMC_15634232","title":"Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification.","date":"2005","source":"Neuropathology and applied neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/15634232","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16482522","id":"PMC_16482522","title":"Astrocyte heterogeneity revealed by expression of a GFAP-LacZ transgene.","date":"2006","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/16482522","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2769798","id":"PMC_2769798","title":"Neuronal modulation of Schwann cell glial fibrillary acidic protein (GFAP).","date":"1989","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/2769798","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18419760","id":"PMC_18419760","title":"Glutamate activates GFAP gene promoter from cultured astrocytes through TGF-beta1 pathways.","date":"2008","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18419760","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25128567","id":"PMC_25128567","title":"Histone acetylation in astrocytes suppresses GFAP and stimulates a reorganization of the intermediate filament network.","date":"2014","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/25128567","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31063456","id":"PMC_31063456","title":"The role of GFAP and vimentin in learning and memory.","date":"2019","source":"Biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31063456","citation_count":53,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29383115","id":"PMC_29383115","title":"Circulating CD9+/GFAP+/survivin+ exosomes in malignant glioma patients following survivin vaccination.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29383115","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"12882814","id":"PMC_12882814","title":"GFAP promoter drives Müller cell-specific expression in transgenic mice.","date":"2003","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/12882814","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16205370","id":"PMC_16205370","title":"Expression of MBP, PLP, MAG, CNP, and GFAP in the Human Alcoholic Brain.","date":"2005","source":"Alcoholism, clinical and experimental research","url":"https://pubmed.ncbi.nlm.nih.gov/16205370","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30355500","id":"PMC_30355500","title":"Mutations in GFAP Disrupt the Distribution and Function of Organelles in Human Astrocytes.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30355500","citation_count":50,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7824058","id":"PMC_7824058","title":"Regional changes in expression of NCAM, GFAP, and S100 in aging rat brain.","date":"1994","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/7824058","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38216970","id":"PMC_38216970","title":"Prediction of clinical progression in nervous system diseases: plasma glial fibrillary acidic protein (GFAP).","date":"2024","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/38216970","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33753498","id":"PMC_33753498","title":"GFAP hyperpalmitoylation exacerbates astrogliosis and neurodegenerative pathology in PPT1-deficient mice.","date":"2021","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33753498","citation_count":46,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7918670","id":"PMC_7918670","title":"Mechanism of S100 protein-dependent inhibition of glial fibrillary acidic protein (GFAP) polymerization.","date":"1994","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/7918670","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2200639","id":"PMC_2200639","title":"Müller cell GFAP expression exhibits gradient from focus of photoreceptor light damage.","date":"1990","source":"Current eye research","url":"https://pubmed.ncbi.nlm.nih.gov/2200639","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27141937","id":"PMC_27141937","title":"GFAP isoforms control intermediate filament network dynamics, cell morphology, and focal adhesions.","date":"2016","source":"Cellular and molecular life sciences : CMLS","url":"https://pubmed.ncbi.nlm.nih.gov/27141937","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19146851","id":"PMC_19146851","title":"Properties of astrocytes cultured from GFAP over-expressing and GFAP mutant mice.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/19146851","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10674496","id":"PMC_10674496","title":"TNF-alpha induced over-expression of GFAP is associated with MAPKs.","date":"2000","source":"Neuroreport","url":"https://pubmed.ncbi.nlm.nih.gov/10674496","citation_count":42,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7890332","id":"PMC_7890332","title":"Normal and pathological expression of GFAP promoter elements in transgenic mice.","date":"1994","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/7890332","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20538881","id":"PMC_20538881","title":"Drug screening to identify suppressors of GFAP expression.","date":"2010","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20538881","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"4034433","id":"PMC_4034433","title":"GFAP in brain tumor diagnosis: possibilities and limitations.","date":"1985","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/4034433","citation_count":39,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23832770","id":"PMC_23832770","title":"Transgenic analysis of GFAP promoter elements.","date":"2013","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/23832770","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"2279327","id":"PMC_2279327","title":"GFAP turnover during astroglial proliferation and differentiation.","date":"1990","source":"Brain research. Developmental brain research","url":"https://pubmed.ncbi.nlm.nih.gov/2279327","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36878332","id":"PMC_36878332","title":"Hippocampal GFAP-positive astrocyte responses to amyloid and tau pathologies.","date":"2023","source":"Brain, behavior, and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/36878332","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26118771","id":"PMC_26118771","title":"Heterogeneity of Notch signaling in astrocytes and the effects of GFAP and vimentin deficiency.","date":"2015","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26118771","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26478912","id":"PMC_26478912","title":"CSF and Blood Levels of GFAP in Alexander Disease.","date":"2015","source":"eNeuro","url":"https://pubmed.ncbi.nlm.nih.gov/26478912","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24269336","id":"PMC_24269336","title":"MeCP2 regulates GFAP expression within the developing brain.","date":"2013","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/24269336","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24696300","id":"PMC_24696300","title":"Silencing GFAP isoforms in astrocytoma cells disturbs laminin-dependent motility and cell adhesion.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/24696300","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33047897","id":"PMC_33047897","title":"Plasma NfL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy.","date":"2020","source":"Annals of clinical and translational neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33047897","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36067832","id":"PMC_36067832","title":"Serum GFAP - reference interval and preanalytical properties in Danish adults.","date":"2022","source":"Clinical chemistry and laboratory medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36067832","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"3705189","id":"PMC_3705189","title":"Anaplasia and heterogeneity of GFAP expression in gliomas.","date":"1986","source":"Tumori","url":"https://pubmed.ncbi.nlm.nih.gov/3705189","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10943999","id":"PMC_10943999","title":"Alterations in levels of mRNAs coding for glial fibrillary acidic protein (GFAP) and vimentin genes in the central nervous system of hens treated with diisopropyl phosphorofluoridate (DFP).","date":"2000","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/10943999","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25178519","id":"PMC_25178519","title":"Immunohistochemical analysis of GFAP-δ and nestin in cerebral astrocytomas.","date":"2014","source":"Brain tumor pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25178519","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33421075","id":"PMC_33421075","title":"Expression of GFAP and Tau Following Blast Exposure in the Cerebral Cortex of Ferrets.","date":"2021","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33421075","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32217788","id":"PMC_32217788","title":"CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD.","date":"2020","source":"Journal of neurology, neurosurgery, and psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/32217788","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22301378","id":"PMC_22301378","title":"Quantitative analysis of GFAP- and S100 protein-immunopositive astrocytes to investigate the severity of traumatic brain injury.","date":"2012","source":"Legal medicine (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/22301378","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32019875","id":"PMC_32019875","title":"Encephalitis with radial perivascular emphasis: Not necessarily associated with GFAP antibodies.","date":"2020","source":"Neurology(R) neuroimmunology & neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/32019875","citation_count":27,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35673702","id":"PMC_35673702","title":"GFAP Alternative Splicing and the Relevance for Disease - A Focus on Diffuse Gliomas.","date":"2022","source":"ASN neuro","url":"https://pubmed.ncbi.nlm.nih.gov/35673702","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1649261","id":"PMC_1649261","title":"Schwann cell GFAP expression increases in axonal neuropathies.","date":"1991","source":"Journal of the neurological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/1649261","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39289040","id":"PMC_39289040","title":"The GFAP proteoform puzzle: How to advance GFAP as a fluid biomarker in neurological diseases.","date":"2024","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/39289040","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26090233","id":"PMC_26090233","title":"Striatal Injury with 6-OHDA Transiently Increases Cerebrospinal GFAP and S100B.","date":"2015","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/26090233","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33493951","id":"PMC_33493951","title":"Complex and regional-specific changes in the morphological complexity of GFAP+ astrocytes in middle-aged mice.","date":"2020","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/33493951","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27063100","id":"PMC_27063100","title":"Effects of enriched environment on alterations in the prefrontal cortex GFAP- and S100B-immunopositive astrocytes and behavioral deficits in MK-801-treated rats.","date":"2016","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/27063100","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27579183","id":"PMC_27579183","title":"Anorexia Reduces GFAP+ Cell Density in the Rat Hippocampus.","date":"2016","source":"Neural plasticity","url":"https://pubmed.ncbi.nlm.nih.gov/27579183","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23991052","id":"PMC_23991052","title":"Alternative mRNA splicing from the glial fibrillary acidic protein (GFAP) gene generates isoforms with distinct subcellular mRNA localization patterns in astrocytes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23991052","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23840007","id":"PMC_23840007","title":"GFAP expression and social deficits in transgenic mice overexpressing human sAPPα.","date":"2013","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/23840007","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26953813","id":"PMC_26953813","title":"Asymmetric Distribution of GFAP in Glioma Multipotent Cells.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26953813","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21987397","id":"PMC_21987397","title":"Archetypal and new families with Alexander disease and novel mutations in GFAP.","date":"2011","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21987397","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31838996","id":"PMC_31838996","title":"Refining the concept of GFAP toxicity in Alexander disease.","date":"2019","source":"Journal of neurodevelopmental disorders","url":"https://pubmed.ncbi.nlm.nih.gov/31838996","citation_count":22,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9097072","id":"PMC_9097072","title":"Astrocyte activation by Sindbis virus: expression of GFAP, cytokines, and adhesion molecules.","date":"1997","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/9097072","citation_count":21,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29852171","id":"PMC_29852171","title":"Mechanisms involved in epigenetic down-regulation of Gfap under maternal hypothyroidism.","date":"2018","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/29852171","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38401182","id":"PMC_38401182","title":"GFAP-isoforms in the nervous system: Understanding the need for diversity.","date":"2024","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38401182","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35896928","id":"PMC_35896928","title":"Serum glial fibrillary acidic protein (GFAP) predicts outcome after intracerebral and subarachnoid hemorrhage.","date":"2022","source":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","url":"https://pubmed.ncbi.nlm.nih.gov/35896928","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28546444","id":"PMC_28546444","title":"Glial fibrillary acidic protein (GFAP) is a novel biomarker for the prediction of autoimmune diabetes.","date":"2017","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/28546444","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37187609","id":"PMC_37187609","title":"Striatal spatial heterogeneity, clustering, and white matter association of GFAP+ astrocytes in a mouse model of Huntington's disease.","date":"2023","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37187609","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9688751","id":"PMC_9688751","title":"Effects of microgravity and bone morphogenetic protein II on GFAP in rat brain.","date":"1998","source":"Journal of applied physiology (Bethesda, Md. : 1985)","url":"https://pubmed.ncbi.nlm.nih.gov/9688751","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35983033","id":"PMC_35983033","title":"Serological biomarkers in autoimmune GFAP astrocytopathy.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35983033","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"20512593","id":"PMC_20512593","title":"Glial cells revealed by GFAP immunoreactivity in fish gut.","date":"2010","source":"Cell and tissue research","url":"https://pubmed.ncbi.nlm.nih.gov/20512593","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38805359","id":"PMC_38805359","title":"Serum NfL and GFAP as biomarkers of progressive neurodegeneration in TBI.","date":"2024","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/38805359","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32907910","id":"PMC_32907910","title":"Discriminative value of glial fibrillar acidic protein (GFAP) as a diagnostic tool in acute stroke. Individual patient data meta-analysis.","date":"2020","source":"Journal of investigative medicine : the official publication of the American Federation for Clinical Research","url":"https://pubmed.ncbi.nlm.nih.gov/32907910","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"14702039","id":"PMC_14702039","title":"Complete sequencing and characterization of 21,243 full-length human cDNAs.","date":"2003","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/14702039","citation_count":754,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11138011","id":"PMC_11138011","title":"Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease.","date":"2001","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11138011","citation_count":547,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8125298","id":"PMC_8125298","title":"Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.","date":"1994","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/8125298","citation_count":492,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25910212","id":"PMC_25910212","title":"Widespread macromolecular interaction perturbations in human genetic disorders.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25910212","citation_count":454,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26871637","id":"PMC_26871637","title":"Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing.","date":"2016","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26871637","citation_count":423,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16344560","id":"PMC_16344560","title":"Diversification of transcriptional modulation: large-scale identification and characterization of putative alternative promoters of human genes.","date":"2005","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/16344560","citation_count":409,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8889548","id":"PMC_8889548","title":"Normalization and subtraction: two approaches to facilitate gene discovery.","date":"1996","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/8889548","citation_count":401,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"27018834","id":"PMC_27018834","title":"Time Course and Diagnostic Accuracy of Glial and Neuronal Blood Biomarkers GFAP and UCH-L1 in a Large Cohort of Trauma Patients With and Without Mild Traumatic Brain Injury.","date":"2016","source":"JAMA neurology","url":"https://pubmed.ncbi.nlm.nih.gov/27018834","citation_count":394,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17500595","id":"PMC_17500595","title":"Huntingtin interacting proteins are genetic modifiers of neurodegeneration.","date":"2007","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17500595","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21079180","id":"PMC_21079180","title":"GFAP and S100B are biomarkers of traumatic brain injury: an observational cohort study.","date":"2010","source":"Neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21079180","citation_count":277,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"30594925","id":"PMC_30594925","title":"Glial Fibrillary Acidic Protein in Serum is Increased in Alzheimer's Disease and Correlates with Cognitive Impairment.","date":"2019","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/30594925","citation_count":257,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35031058","id":"PMC_35031058","title":"EWSR1-induced circNEIL3 promotes glioma progression and exosome-mediated macrophage immunosuppressive polarization via stabilizing IGF2BP3.","date":"2022","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35031058","citation_count":257,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15174051","id":"PMC_15174051","title":"An investigation into the human serum \"interactome\".","date":"2004","source":"Electrophoresis","url":"https://pubmed.ncbi.nlm.nih.gov/15174051","citation_count":247,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"2780570","id":"PMC_2780570","title":"Changes in brain gene expression shared by scrapie and Alzheimer disease.","date":"1989","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/2780570","citation_count":244,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33773595","id":"PMC_33773595","title":"Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment.","date":"2021","source":"Alzheimer's research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/33773595","citation_count":229,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20176123","id":"PMC_20176123","title":"Chaperone-mediated autophagy: molecular mechanisms and physiological relevance.","date":"2010","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/20176123","citation_count":210,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"37174709","id":"PMC_37174709","title":"GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37174709","citation_count":209,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21988832","id":"PMC_21988832","title":"Toward an understanding of the protein interaction network of the human liver.","date":"2011","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/21988832","citation_count":207,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15732097","id":"PMC_15732097","title":"Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease.","date":"2005","source":"Annals of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15732097","citation_count":202,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26742791","id":"PMC_26742791","title":"Density of GFAP-immunoreactive astrocytes is decreased in left hippocampi in major depressive disorder.","date":"2015","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/26742791","citation_count":202,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45615,"output_tokens":4815,"usd":0.104535},"stage2":{"model":"claude-opus-4-6","input_tokens":8465,"output_tokens":3745,"usd":0.203925},"total_usd":0.643229,"stage1_batch_id":"msgbatch_01DzrsgVgYngY1hvM3DU1yF2","stage2_batch_id":"msgbatch_01KA9b7iRzKFdhoBUT7vCvSe","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":58909,"output_tokens":4936,"usd":0.125384},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":8828,"output_tokens":3818,"usd":0.209385}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1985,\n      \"finding\": \"GFAP is the major protein constituent of glial intermediate filaments in differentiated fibrous and protoplasmic astrocytes of the CNS, serving a structural role as a cytoskeletal component that defines and maintains astrocyte shape.\",\n      \"method\": \"Biochemical characterization, immunochemistry\",\n      \"journal\": \"Journal of neuroimmunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — foundational characterization replicated across many labs, forms the basis of the entire field\",\n      \"pmids\": [\"2409105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"S100 protein inhibits GFAP polymerization in a Ca2+-dependent manner by interfering with nucleation and polymer growth, sequestering soluble GFAP, and disassembling preformed glial filaments, suggesting S100 regulates GFAP assembly dynamics in response to elevated intracellular Ca2+.\",\n      \"method\": \"Sedimentation assay, viscometry, in vitro polymerization assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with mechanistic detail (nucleation, elongation, stoichiometry)\",\n      \"pmids\": [\"7918670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A ~2 kb 5'-flanking region of the human GFAP gene is sufficient to direct astrocyte-specific expression in transgenic mice and supports upregulation following brain injury, demonstrating that astrocyte-specific and injury-responsive transcriptional elements reside within this promoter segment.\",\n      \"method\": \"Transgenic mouse reporter assay (lacZ)\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vivo functional demonstration, replicated by multiple labs\",\n      \"pmids\": [\"8120611\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"GFAP-null mice generated by gene targeting have astrocytes with severely reduced intermediate filaments and display enhanced long-term potentiation in hippocampal CA1, demonstrating that GFAP is required for normal astrocyte-mediated modulation of synaptic efficacy.\",\n      \"method\": \"Gene targeting (knockout mouse), electrophysiology (LTP recording)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic KO with defined physiological phenotype\",\n      \"pmids\": [\"8692820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Transgenic overexpression of GFAP in mice causes astrocyte hypertrophy, upregulation of small heat-shock proteins, and formation of Rosenthal fiber inclusion bodies identical to those in Alexander disease, demonstrating that excess GFAP protein per se is sufficient to disrupt astrocyte function and cause fatal encephalopathy.\",\n      \"method\": \"Transgenic mouse overexpression, histology, immunostaining\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — transgenic gain-of-function with defined cellular and organismal phenotype\",\n      \"pmids\": [\"9466565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TGF-β1 increases GFAP mRNA and protein in cultured astrocytes, while FGF-2 decreases GFAP expression and inhibits TGF-β1-induced upregulation via FGF receptor tyrosine kinase signaling, demonstrating opposing growth factor regulation of the GFAP cytoskeleton.\",\n      \"method\": \"Primary astrocyte culture, Northern/Western blot, pharmacological inhibition of FGFR\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple methods in single lab, direct mechanistic pathway identification\",\n      \"pmids\": [\"9537840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TNF-α induces overexpression of GFAP in cultured astrocytes via activation of the MAPK/Erk2 signaling pathway, as demonstrated by the MAPK inhibitor PD98059 significantly attenuating TNF-α-induced GFAP upregulation.\",\n      \"method\": \"Primary astrocyte culture, Western blot, pharmacological inhibition\",\n      \"journal\": \"Neuroreport\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, single method, direct pathway placement\",\n      \"pmids\": [\"10674496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Glutamate activates the GFAP gene promoter in astrocytes through metabotropic glutamate receptor (mGluR2/3) signaling, triggering TGF-β1 secretion and subsequent Smad nuclear translocation, with MAPK and PI3K pathways required for TGF-β1-induced GFAP gene activation.\",\n      \"method\": \"Transgenic reporter assay (β-gal), neutralizing antibodies, pathway inhibitors, Smad translocation assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods, defined signaling pathway from receptor to promoter activation\",\n      \"pmids\": [\"18419760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"A 55 bp segment (bp -1488 to -1434) of the GFAP promoter contains region-specific regulatory elements, and a 45 bp sequence (bp -1443 to -1399) silences expression in neurons; transcription factors NFI, SP1, STAT3, and NF-κB are important for regulating GFAP promoter strength and astrocyte specificity.\",\n      \"method\": \"Transgenic mouse analysis with promoter deletion/mutation constructs\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct in vivo promoter dissection with defined functional elements across multiple transgenic lines\",\n      \"pmids\": [\"18240313\", \"23832770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"αB-crystallin (Cryab) regulates GFAP assembly and suppresses GFAP toxicity in astrocytes; loss of Cryab increases mortality in GFAP-overexpressing mice, while transgenic overexpression of Cryab in AxD mouse models reduces CNS stress response, restores glutamate transporter Glt1 (EAAT2) expression, and prevents death from seizures.\",\n      \"method\": \"Genetic crosses of transgenic/knockout mice, survival analysis, Western blot, immunostaining\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple genetic models with defined molecular and functional outcomes\",\n      \"pmids\": [\"19129171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Mutant GFAP (AxD-associated mutations) and excess wild-type GFAP both promote cytoplasmic inclusion formation, disrupt the cytoskeleton, decrease cell proliferation, increase cell death, reduce proteasomal function, and compromise astrocyte stress resistance in primary cultures.\",\n      \"method\": \"Primary astrocyte cultures from transgenic/knock-in mice, immunostaining, flow cytometry, proteasome activity assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple cellular phenotypes measured with direct experimental models\",\n      \"pmids\": [\"19146851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GFAP alternative splicing generates isoforms (GFAPα and GFAPδ) with distinct subcellular mRNA localization patterns in astrocytes; GFAPα mRNA is preferentially localized to astrocyte protrusions compared to GFAPδ mRNA, and this differential localization depends on their distinct 3'-exon sequences.\",\n      \"method\": \"RT-qPCR, immunofluorescence, subcellular fractionation/in situ hybridization\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization experiments with mechanistic link to 3' exon sequences\",\n      \"pmids\": [\"23991052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"HDAC inhibition reduces GFAP transcription in human astrocytes, shifts isoform expression toward GFAPδ (via altered SR protein-dependent splicing), and causes aggregation of the GFAP intermediate filament network, demonstrating that histone acetylation controls GFAP expression and IF organization in mature astrocytes.\",\n      \"method\": \"HDAC inhibitor treatment, Western blot, immunofluorescence, splicing factor knockdown\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods in primary human cells with mechanistic pathway identification\",\n      \"pmids\": [\"25128567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"GFAPα isoform-specific silencing in astrocytoma cells induces a change in integrin expression, decreases plectin, increases laminin, and significantly reduces cell motility; knockdown of all GFAP isoforms decreases cell spreading and increases laminin adhesion, revealing distinct isoform-specific roles in extracellular matrix interactions.\",\n      \"method\": \"shRNA knockdown, cell motility assay, adhesion assay, immunostaining\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific knockdown with defined functional readouts\",\n      \"pmids\": [\"24696300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GFAPδ exchanges more slowly with the intermediate filament network than GFAPα (measured by FRAP), and a GFAPδ-induced collapsed IF network further decreases exchange rates of both isoforms, alters cell morphology, and changes focal adhesion size without affecting migration or proliferation.\",\n      \"method\": \"FRAP (live cell imaging), immunofluorescence, morphometric analysis\",\n      \"journal\": \"Cellular and molecular life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — quantitative live-cell imaging with functional consequences of altered network dynamics\",\n      \"pmids\": [\"27141937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AxD patient-derived iPSC astrocytes with GFAP mutations display GFAP aggregates, enlarged and perinuclearly localized endoplasmic reticulum and lysosomes, impaired extracellular ATP release, and attenuated calcium wave propagation, demonstrating that mutant GFAP disrupts intracellular vesicle regulation and astrocyte secretory function.\",\n      \"method\": \"iPSC-derived astrocytes, isogenic controls, RNA-seq, organelle imaging, ATP release assay, calcium imaging\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — human iPSC isogenic model with multiple orthogonal methods and direct functional readouts\",\n      \"pmids\": [\"30355500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GFAP is palmitoylated in vitro and in vivo at cysteine-291 as the unique palmitoylated residue; PPT1 depalmitoylates GFAP; palmitoylated GFAP promotes astrocyte proliferation; mutation of C291A attenuates astrogliosis and neurodegenerative pathology in PPT1-knockin mice.\",\n      \"method\": \"Palm-proteomics, in vitro palmitoylation assay, mutagenesis (C291A), mouse genetics, immunostaining\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro and in vivo palmitoylation with mutagenesis and functional rescue/attenuation\",\n      \"pmids\": [\"33753498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MeCP2 regulates GFAP expression by binding to methylated regions of the GFAP promoter; siRNA knockdown of MeCP2 in the developing rat brain increases GFAP mRNA and protein in a sex-specific (female-specific) manner without affecting S100β or vimentin.\",\n      \"method\": \"siRNA knockdown in vivo, RT-PCR, Western blot\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct in vivo intervention with mechanistic link to GFAP promoter methylation\",\n      \"pmids\": [\"24269336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Maternal hypothyroidism epigenetically silences Gfap expression in rat neocortex via increased DNA methylation and decreased histone acetylation at the Gfap promoter, accompanied by increased HDAC activity; TH supplementation reverses these changes.\",\n      \"method\": \"ChIP (histone acetylation), bisulfite sequencing (DNA methylation), HDAC activity assay, RT-PCR\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple epigenetic methods directly at the GFAP promoter with functional validation\",\n      \"pmids\": [\"29852171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Neurons secrete brain region-specific soluble factors that activate the GFAP gene promoter in astrocytes, inducing cell cycle arrest and glial differentiation; conditioned medium from cerebral hemisphere neurons mimics this effect in a region-specific manner.\",\n      \"method\": \"Co-culture of transgenic reporter astrocytes with neurons, conditioned medium experiments, β-galactosidase reporter assay\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — reporter assay with conditioned medium; mechanism partially resolved (soluble factor, region-specific)\",\n      \"pmids\": [\"10384875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1989,\n      \"finding\": \"Schwann cells express GFAP selectively in association with small axons; sciatic nerve transection markedly reduces GFAP mRNA in the distal stump, demonstrating that Schwann cell GFAP expression is developmentally regulated and requires ongoing trophic input from small axons.\",\n      \"method\": \"Immunohistology, Northern blot, nerve transection\",\n      \"journal\": \"Journal of neuroscience research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct axonal dependency demonstrated by nerve transection with mRNA quantification\",\n      \"pmids\": [\"2769798\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"GFAP and vimentin deficiency in astrocytes (GFAP-/-Vim-/- mice) decreases Notch signal-sending competence in astrocytes and alters expression of Notch signaling pathway genes (Dlk2, Notch1, Sox2), placing the astrocyte intermediate filament network upstream of Notch-mediated astrocyte-neurogenesis regulation.\",\n      \"method\": \"Single-cell RT-qPCR, GFAP/Vimentin double KO mice, freshly isolated astrocytes\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific pathway gene expression changes in isolated cells\",\n      \"pmids\": [\"26118771\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GFAP and vimentin double-knockout mice show more pronounced memory extinction compared to wildtype in IntelliCage reversal learning, indicating that the astrocyte intermediate filament network containing GFAP modulates hippocampal circuit reorganization and memory extinction.\",\n      \"method\": \"GFAP-/-Vim-/- knockout mouse, behavioral testing (IntelliCage, Morris water maze, fear conditioning)\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific behavioral phenotype; confounded by vimentin co-deletion\",\n      \"pmids\": [\"31063456\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GFAP is the principal type III intermediate filament protein of astrocytes that provides structural support to the cytoskeleton and whose assembly is dynamically regulated by binding partners including S100 (Ca2+-dependent disassembly) and αB-crystallin; its expression is controlled at multiple levels including transcriptional regulation by STAT3, NFI, SP1, NF-κB, MeCP2, TGF-β1/Smad, MAPK, and epigenetic mechanisms (DNA methylation, histone acetylation/HDAC), and post-translationally by palmitoylation at C291 (written by PATs, erased by PPT1); GFAP isoforms (GFAPα vs GFAPδ) differ in IF network exchange dynamics and mRNA localization, with isoform composition controlling cell morphology, focal adhesions, and extracellular matrix interactions; loss of GFAP impairs astrocyte-mediated modulation of synaptic plasticity (LTP), and mutant or excess GFAP disrupts vesicle/organelle distribution, impairs ATP secretion and calcium signaling, and causes Rosenthal fiber formation characteristic of Alexander disease.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"GFAP-null mice (generated by gene targeting in embryonic stem cells) showed severely reduced intermediate filaments in astrocytes and exhibited enhanced long-term potentiation (both population spike amplitude and EPSP slope) in the CA1 hippocampal region compared to controls, demonstrating that GFAP is required for normal astrocyte-neuronal interactions that modulate synaptic efficacy.\",\n      \"method\": \"Gene targeting (knockout mouse), electrophysiological recording of LTP in hippocampal slices\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and physiological phenotype, well-controlled study\",\n      \"pmids\": [\"8692820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"S100 protein (a Ca2+-binding protein) binds directly to GFAP and inhibits its polymerization in a Ca2+-dependent manner: it interferes with nucleation and polymer growth, reduces the rate and extent of GFAP assembly, increases the critical concentration for assembly, and disassembles preformed glial filaments, suggesting S100 regulates glial filament dynamics in response to elevated intracellular Ca2+.\",\n      \"method\": \"Sedimentation assay, viscometry, in vitro polymerization assay\",\n      \"journal\": \"Biochimica et biophysica acta\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro assembly assay with quantitative kinetic analysis and stoichiometry\",\n      \"pmids\": [\"7918670\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Dominant missense mutations in the coding region of GFAP cause Alexander disease, establishing GFAP as the first identified gene whose primary mutation causes an astrocyte disorder; mutant GFAP leads to formation of Rosenthal fiber inclusions in astrocytes.\",\n      \"method\": \"DNA sequence analysis of patient samples, cellular transfection assays with mutant constructs\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple patient cohorts with sequence validation and functional transfection assays; independently replicated across multiple studies\",\n      \"pmids\": [\"11138011\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Transgenic mice overexpressing human GFAP develop astrocyte hypertrophy, upregulate small heat-shock proteins, and form cytoplasmic inclusion bodies (Rosenthal fibers) identical to those in Alexander disease, resulting in fatal encephalopathy; this established that elevated GFAP levels per se alter astrocyte function and cause pathology.\",\n      \"method\": \"Transgenic mouse overexpression, histological and immunohistochemical analysis\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain-of-function with defined cellular and organismal phenotype; replicated in subsequent studies\",\n      \"pmids\": [\"9466565\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"alphaB-crystallin (Cryab) regulates GFAP assembly and suppresses GFAP toxicity in Alexander disease mouse models: loss of Cryab increased mortality in GFAP-overexpressing mice, while transgenic elevation of Cryab rescued animals from terminal seizures, restored glutamate transporter Glt1 (EAAT2) expression, and reduced the CNS stress response, demonstrating an astrocyte-specific protective mechanism.\",\n      \"method\": \"Genetic crosses of mouse models (GFAP overexpressor × Cryab-null; AxD mutation knock-in × Cryab transgenic), survival analysis, immunohistochemistry, western blot\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis via multiple genetic combinations with defined molecular and phenotypic readouts\",\n      \"pmids\": [\"19129171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"GFAP is palmitoylated in vitro and in vivo, with cysteine-291 identified as the unique palmitoylation site; PPT1 depalmitoylates GFAP. Hyperpalmitoylated GFAP promotes astrocyte proliferation, and in PPT1-deficient mice elevated palmitoylated GFAP accelerates astrogliosis. Mutation of Cys-291 to Ala attenuates astrogliosis and concurrent neurodegenerative pathology in PPT1-knockin mice.\",\n      \"method\": \"Palm-proteomics, in vitro palmitoylation assay, site-directed mutagenesis (C291A knock-in), cell proliferation assay, in vivo mouse model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro assay + site-specific mutagenesis + in vivo genetic rescue in the same study\",\n      \"pmids\": [\"33753498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"GFAPδ and GFAPα isoforms differ in their exchange dynamics within the intermediate filament network: FRAP experiments showed GFP-GFAPδ exchanges significantly more slowly than GFP-GFAPα; GFAPδ-induced network collapse further decreased recovery of both isoforms and altered cell morphology and focal adhesion size without affecting migration or proliferation.\",\n      \"method\": \"Fluorescence recovery after photobleaching (FRAP), live-cell imaging, focal adhesion analysis in astrocytoma cells\",\n      \"journal\": \"Cellular and molecular life sciences : CMLS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization and dynamics experiment with functional consequence (focal adhesion size, morphology); single lab\",\n      \"pmids\": [\"27141937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Isoform-specific silencing of GFAPα (canonical) in astrocytoma cells shifted the GFAPδ:GFAPα ratio, leading to changes in integrin expression, decreased plectin, increased laminin, and significantly decreased cell motility. Pan-GFAP knockdown caused decreased cell spreading, increased integrin expression, and >100-fold increased adhesion to laminin, demonstrating distinct isoform-specific roles of GFAP in regulating astrocyte–extracellular matrix interactions.\",\n      \"method\": \"shRNA-mediated isoform-specific knockdown, cell motility assay, adhesion assay, integrin and ECM protein analysis\",\n      \"journal\": \"FASEB journal : official publication of the Federation of American Societies for Experimental Biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — isoform-specific KD with multiple orthogonal functional readouts; single lab\",\n      \"pmids\": [\"24696300\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Histone deacetylase (HDAC) inhibition (trichostatin A or sodium butyrate) reduced GFAP transcription in human astrocytes and astrocytoma cells, and the reduced transcription increased the GFAPδ:GFAPα ratio by promoting alternative splicing dependent on SR protein splicing factors; HDAC inhibition also caused GFAP network aggregation similar to GFAPδ-induced network collapse.\",\n      \"method\": \"HDAC inhibitor treatment, RT-qPCR, western blot, immunofluorescence, splicing factor analysis in primary human astrocytes and astrocytoma cells\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods linking histone acetylation to GFAP transcription, splicing, and network organization; single lab\",\n      \"pmids\": [\"25128567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"AxD patient-derived iPSC astrocytes carrying GFAP mutations (corrected by gene editing as isogenic controls) displayed GFAP aggregates, perinuclear redistribution of ER and lysosomes, impaired extracellular ATP release, and attenuated calcium wave propagation, demonstrating that AxD mutations in GFAP disrupt intracellular vesicle regulation and astrocyte secretory function.\",\n      \"method\": \"iPSC derivation from AxD patients, CRISPR/Cas9 isogenic correction, RNA-seq, organelle imaging, ATP release assay, calcium imaging\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — isogenic human iPSC model with multiple orthogonal functional and cell biological readouts\",\n      \"pmids\": [\"30355500\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Primary astrocytes from Alexander disease mouse models (GFAP overexpressor transgenic and AxD-mutation knock-in) showed that both mutant GFAP and excess wild-type GFAP promote cytoplasmic inclusion formation, disrupt the cytoskeleton, decrease cell proliferation, increase cell death, reduce proteasomal function, and compromise stress resistance.\",\n      \"method\": \"Primary astrocyte culture from transgenic and knock-in mice, immunocytochemistry, cell proliferation and death assays, proteasome activity assay\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — comparison of two genetic models with multiple functional readouts; single lab\",\n      \"pmids\": [\"19146851\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Glutamate activates the GFAP gene promoter in cortical astrocytes via metabotropic glutamate receptors (blocked by mGluR2/3 antagonist MCPG) and is mediated by TGF-β1 secretion, leading to Smad-2 nuclear translocation and requiring cooperative activation of both MAPK/ERK and PI3K pathways alongside the canonical TGF-β/Smad pathway.\",\n      \"method\": \"Transgenic GFAP-lacZ reporter astrocytes, neutralizing antibodies, pharmacological inhibitors (MCPG, PD98059, LY294002), Smad nuclear translocation assay\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple pathway inhibitors and reporter assay in primary cells; single lab\",\n      \"pmids\": [\"18419760\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Mutant GFAP behavior in cellular transfection assays confirmed that pathogenic Alexander disease mutations produce a gain-of-function leading to Rosenthal fiber formation, and expanded the catalog of causative mutations across infantile, juvenile, and adult forms of the disease.\",\n      \"method\": \"DNA sequencing of patient cohorts, cellular transfection assays\",\n      \"journal\": \"Annals of neurology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — large multi-center cohort with functional transfection validation; replicated across forms of disease\",\n      \"pmids\": [\"15732097\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"TNF-α treatment of cultured astrocytes caused dramatic GFAP over-expression associated with substantial activation of MAPK Erk2; this over-expression was significantly attenuated by the MAPK inhibitor PD98059, placing TNF-α–MAPK signaling upstream of GFAP upregulation.\",\n      \"method\": \"Astrocyte cell culture, western blot, pharmacological MAPK inhibition (PD98059)\",\n      \"journal\": \"Neuroreport\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single lab, pharmacological inhibition without genetic confirmation\",\n      \"pmids\": [\"10674496\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"TGF-β1 significantly increased GFAP mRNA and protein in cultured astrocytes without morphological change, while FGF-2 (acting through tyrosine kinase/FGFR autophosphorylation, blocked by 5′-methylthioadenosine) decreased GFAP mRNA and protein and also inhibited TGF-β1-mediated GFAP induction; cycloheximide blocked FGF-2 inhibition of TGF-β1-mediated GFAP mRNA increase only when both were applied together, indicating a protein-synthesis-dependent counter-regulatory mechanism.\",\n      \"method\": \"Astrocyte culture, northern blot, western blot, pharmacological inhibition, cycloheximide chase\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple growth factors, pharmacological dissection of receptor kinase involvement, protein synthesis requirement tested orthogonally\",\n      \"pmids\": [\"9537840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Alternative splicing of GFAP generates isoforms (GFAPα and GFAPδ) with distinct subcellular mRNA localization: a larger fraction of GFAPα mRNA localizes to astrocyte protrusions compared to GFAPδ mRNA, and this differential localization depends on the distinct 3′-exon sequences of each isoform.\",\n      \"method\": \"RT-qPCR, immunofluorescence, subcellular mRNA fractionation, fluorescence in situ hybridization in primary mouse astrocytes\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct mRNA localization experiment with 3′-exon-swapping evidence; single lab\",\n      \"pmids\": [\"23991052\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"MeCP2 binds to methylated regions of the GFAP promoter and suppresses GFAP expression; transient siRNA knockdown of MeCP2 in the neonatal rat amygdala and hypothalamus increased GFAP mRNA and protein specifically in females but not males, without altering other astrocyte markers (S100β, vimentin), demonstrating sex-specific epigenetic regulation of GFAP by MeCP2.\",\n      \"method\": \"In vivo siRNA knockdown, RT-qPCR, western blot, immunohistochemistry in rat brain\",\n      \"journal\": \"Brain research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo KD with region-specific and sex-specific specificity controls; single lab\",\n      \"pmids\": [\"24269336\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Maternal hypothyroidism causes epigenetic silencing of Gfap in developing neocortex via increased DNA methylation and decreased histone acetylation at the Gfap promoter, coupled with increased HDAC activity; thyroid hormone supplementation reversed these changes, demonstrating that thyroid hormone regulates GFAP transcription through coordinated DNA methylation and histone modification.\",\n      \"method\": \"Rat model of maternal hypothyroidism, bisulfite sequencing, ChIP for histone acetylation, HDAC activity assay, RT-qPCR, western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple epigenetic methods in vivo with rescue by hormone supplementation; single lab\",\n      \"pmids\": [\"29852171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Transgenic analysis identified NFI, SP1, STAT3, and NF-κB binding sites within the human GFAP promoter as important regulators of promoter strength and/or astrocyte specificity, while mutation of a conserved AP-1 site had little effect; mutation of the B region (bp -1612 to -1489) spanning four contiguous sequences cooperatively reduced transgene activity by ≥50% each, indicating that multiple sites contribute cooperatively to GFAP transcriptional regulation.\",\n      \"method\": \"Transgenic mice carrying block-mutant and site-specific mutant GFAP-reporter constructs, in vivo reporter expression analysis\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic dissection of promoter elements with multiple mutations tested; single lab\",\n      \"pmids\": [\"23832770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"GFAP-null/Vimentin-null (GFAP−/−Vim−/−) double-knockout mice showed more pronounced memory extinction compared to wild-type in IntelliCage reversal learning tasks, while overall locomotion, learning in Morris water maze, and trace fear conditioning were comparable, indicating that the astrocyte intermediate filament system (GFAP + vimentin together) modulates hippocampal circuit reorganization underlying memory extinction.\",\n      \"method\": \"Double-knockout mice, open field, object recognition, Morris water maze, trace fear conditioning, IntelliCage reversal learning\",\n      \"journal\": \"Biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO with specific behavioral phenotype; however phenotype is specific to combined GFAP/vimentin loss\",\n      \"pmids\": [\"31063456\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"GFAP is the principal type III intermediate filament protein of mature astrocytes, functioning as the structural backbone of the astrocyte cytoskeleton; its polymerization is regulated by Ca²⁺-dependent S100 protein binding and by post-translational palmitoylation at Cys-291 (reversed by PPT1); transcription is controlled by a cooperative promoter network involving STAT3, NFI, SP1, and NF-κB, as well as by epigenetic mechanisms (DNA methylation, histone acetylation/MeCP2), and by TGF-β1/Smad–MAPK/PI3K signaling downstream of glutamate and TGF-β1; GFAP is required for normal astrocyte–neuron interactions that constrain hippocampal LTP, and dominant missense mutations or excess GFAP cause Alexander disease through protein aggregation (Rosenthal fibers), impaired vesicle trafficking and ATP secretion, disrupted organelle distribution, and reduced proteasomal function, a pathological cascade that is suppressed by alphaB-crystallin acting in an astrocyte-specific manner.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"GFAP is the principal type III intermediate filament protein of astrocytes, serving as the major structural cytoskeletal element that defines astrocyte morphology and participates in astrocyte-mediated regulation of synaptic plasticity, vesicle trafficking, and intercellular signaling [PMID:2409105, PMID:8692820, PMID:30355500]. GFAP filament assembly is dynamically regulated by S100-mediated Ca²⁺-dependent disassembly and by αB-crystallin, which suppresses GFAP aggregation toxicity; loss of αB-crystallin exacerbates GFAP-driven pathology in Alexander disease models [PMID:7918670, PMID:19129171]. Transcription of GFAP is controlled by a proximal promoter containing NFI, SP1, STAT3, and NF-κB sites, with activity modulated by TGF-β1/Smad and MAPK signaling, MeCP2-dependent promoter methylation, and histone acetylation state, while alternative splicing generates GFAPα and GFAPδ isoforms that differ in network exchange dynamics, mRNA localization, and effects on cell adhesion and morphology [PMID:18240313, PMID:18419760, PMID:25128567, PMID:27141937]. Dominant missense mutations in GFAP or excess wild-type protein cause Rosenthal fiber formation, organelle redistribution, impaired ATP secretion, and fatal encephalopathy characteristic of Alexander disease, and GFAP function is further regulated post-translationally by palmitoylation at Cys-291, which promotes astrocyte proliferation and astrogliosis [PMID:9466565, PMID:30355500, PMID:33753498].\",\n  \"teleology\": [\n    {\n      \"year\": 1985,\n      \"claim\": \"Establishing GFAP as the defining structural intermediate filament protein of astrocytes resolved the molecular identity of glial filaments and provided the foundation for all subsequent mechanistic work on astrocyte cytoskeletal biology.\",\n      \"evidence\": \"Biochemical characterization and immunochemistry of glial intermediate filaments\",\n      \"pmids\": [\"2409105\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No information on how GFAP assembly is regulated\", \"No functional consequences of GFAP loss known at this point\"]\n    },\n    {\n      \"year\": 1989,\n      \"claim\": \"Demonstrating that Schwann cell GFAP expression depends on axonal contact established that GFAP is not constitutive but regulated by extrinsic trophic signals, extending its expression beyond astrocytes to peripheral glia.\",\n      \"evidence\": \"Sciatic nerve transection with Northern blot and immunohistology in Schwann cells\",\n      \"pmids\": [\"2769798\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the axon-derived trophic factor unknown\", \"Mechanism of axon-dependent transcriptional regulation unresolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Reconstitution of S100-mediated Ca²⁺-dependent inhibition of GFAP polymerization provided the first defined molecular mechanism for dynamic regulation of the glial filament network, linking calcium signaling to cytoskeletal remodeling.\",\n      \"evidence\": \"In vitro sedimentation and viscometry assays with purified GFAP and S100\",\n      \"pmids\": [\"7918670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo relevance of S100-GFAP interaction not demonstrated\", \"Stoichiometry and binding site on GFAP not mapped\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Defining a ~2 kb promoter sufficient for astrocyte-specific and injury-responsive GFAP expression in transgenic mice established the cis-regulatory framework for understanding GFAP transcriptional control.\",\n      \"evidence\": \"Transgenic mouse lacZ reporter driven by GFAP 5'-flanking region\",\n      \"pmids\": [\"8120611\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Individual transcription factor binding sites not yet mapped\", \"Injury-responsive elements not narrowed within the 2 kb region\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"GFAP knockout mice revealed that the astrocyte intermediate filament network is dispensable for gross brain development but required for normal modulation of hippocampal synaptic plasticity, establishing a non-structural physiological role for GFAP.\",\n      \"evidence\": \"Gene-targeted GFAP-null mice with hippocampal electrophysiology (LTP recording)\",\n      \"pmids\": [\"8692820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which GFAP absence enhances LTP is unknown\", \"Relative contribution of GFAP vs vimentin filaments not separated\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Transgenic GFAP overexpression producing Rosenthal fibers and fatal encephalopathy demonstrated that excess GFAP protein is sufficient to cause Alexander disease pathology, shifting the disease model from loss-of-function to toxic gain-of-function.\",\n      \"evidence\": \"Transgenic mice overexpressing wild-type human GFAP; histology and immunostaining\",\n      \"pmids\": [\"9466565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether specific mutations enhance toxicity beyond overexpression not yet tested\", \"Mechanism of Rosenthal fiber nucleation not defined\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Opposing regulation of GFAP by TGF-β1 (upregulation) and FGF-2 (downregulation via FGFR kinase) placed GFAP transcription under growth factor signaling control and explained how cytokine balance regulates reactive astrogliosis.\",\n      \"evidence\": \"Primary astrocyte culture with Northern/Western blot and FGFR pharmacological inhibition\",\n      \"pmids\": [\"9537840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Downstream transcription factors mediating FGF-2 suppression not identified\", \"In vivo relevance during injury not confirmed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"TNF-α-induced GFAP upregulation via MAPK/Erk2 connected inflammatory cytokine signaling to the GFAP promoter, providing a specific signaling cascade for inflammation-driven astrogliosis.\",\n      \"evidence\": \"Primary astrocyte culture with PD98059 (MEK inhibitor) and Western blot\",\n      \"pmids\": [\"10674496\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct transcription factor target of Erk2 at the GFAP promoter not identified\", \"Single pharmacological inhibitor approach\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of specific promoter elements (NFI, SP1, STAT3, NF-κB sites) and the glutamate→mGluR2/3→TGF-β1→Smad signaling axis converging on the GFAP promoter provided an integrated transcription factor–signal transduction map for astrocyte-specific GFAP regulation.\",\n      \"evidence\": \"Transgenic promoter deletion/mutation constructs in mice; reporter assays with neutralizing antibodies, pathway inhibitors, and Smad translocation analysis\",\n      \"pmids\": [\"18240313\", \"18419760\", \"23832770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Combinatorial logic of transcription factor binding not resolved\", \"Chromatin-level regulation at these sites not addressed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Genetic demonstration that αB-crystallin modulates GFAP assembly toxicity in vivo — with Cryab loss increasing and Cryab overexpression decreasing Alexander disease severity — identified the first endogenous protein quality control mechanism for GFAP filaments.\",\n      \"evidence\": \"Genetic crosses of Cryab KO and overexpression transgenics with GFAP-overexpressing/AxD mice; survival, Western blot, immunostaining\",\n      \"pmids\": [\"19129171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Biochemical mechanism of αB-crystallin–GFAP interaction not structurally defined\", \"Whether other small HSPs compensate in vivo unknown\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Discovery that MeCP2 represses GFAP via promoter methylation and that GFAPα and GFAPδ mRNAs localize to distinct subcellular compartments added epigenetic and post-transcriptional layers to GFAP regulation, explaining cell-type and sex-specific expression patterns.\",\n      \"evidence\": \"In vivo MeCP2 siRNA knockdown with RT-PCR/Western; subcellular mRNA fractionation and in situ hybridization for GFAP isoforms\",\n      \"pmids\": [\"24269336\", \"23991052\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific methylated CpGs mediating MeCP2 repression not mapped\", \"Functional consequence of differential mRNA localization at the protein level unclear\", \"Sex-specific mechanism not elucidated\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"HDAC inhibition reduced GFAP transcription and shifted splicing toward GFAPδ via SR protein-dependent mechanisms, while isoform-specific knockdowns revealed distinct roles for GFAPα in cell motility and ECM interactions, establishing that chromatin state and alternative splicing jointly determine GFAP's functional output.\",\n      \"evidence\": \"HDAC inhibitor treatment in human astrocytes; shRNA isoform-specific knockdown in astrocytoma cells with motility, adhesion, and integrin profiling\",\n      \"pmids\": [\"25128567\", \"24696300\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Specific HDACs responsible not identified\", \"In vivo isoform-specific functions not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"FRAP measurements showed GFAPδ exchanges more slowly in the filament network than GFAPα, and a GFAPδ-collapsed network alters focal adhesion size, linking isoform-specific polymer dynamics to cell morphology and adhesion.\",\n      \"evidence\": \"Live-cell FRAP imaging with morphometric and focal adhesion analysis\",\n      \"pmids\": [\"27141937\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis for differential exchange rates unknown\", \"Relevance to in vivo astrocyte heterogeneity not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Alexander disease iPSC-astrocytes demonstrated that GFAP mutations disrupt ER and lysosome positioning, impair ATP secretion, and attenuate calcium wave propagation, extending GFAP's role from structural scaffold to regulator of organelle distribution and gliotransmission.\",\n      \"evidence\": \"iPSC-derived astrocytes with isogenic controls; organelle imaging, ATP release assay, calcium imaging, RNA-seq\",\n      \"pmids\": [\"30355500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking GFAP aggregates to organelle mispositioning unknown\", \"Whether secretory defects are primary or secondary to ER stress unresolved\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Epigenetic silencing of GFAP by increased promoter DNA methylation and decreased histone acetylation under maternal hypothyroidism, reversed by thyroid hormone supplementation, demonstrated hormonal control of astrocyte differentiation via chromatin remodeling at the GFAP locus.\",\n      \"evidence\": \"ChIP for histone acetylation, bisulfite sequencing, and HDAC activity assay in rat neocortex\",\n      \"pmids\": [\"29852171\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which thyroid hormone receptor isoform mediates the effect not determined\", \"Whether effect is direct or via intermediate signaling not resolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identification of Cys-291 as the sole GFAP palmitoylation site, with PPT1 as the erasing enzyme and palmitoylation promoting astrocyte proliferation and astrogliosis, revealed a reversible lipid modification that dynamically tunes GFAP function in health and neurodegeneration.\",\n      \"evidence\": \"Palm-proteomics, in vitro palmitoylation assay, C291A mutagenesis, PPT1-knockin mouse genetics\",\n      \"pmids\": [\"33753498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Palmitoyl acyltransferase(s) writing GFAP palmitoylation not identified\", \"Mechanism by which palmitoylation promotes proliferation unknown\", \"Whether palmitoylation affects filament assembly kinetics not tested\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis for GFAP filament assembly, how GFAP aggregates mechanistically redistribute organelles, and the identity of the palmitoyl acyltransferase(s) that palmitoylate GFAP remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of assembled GFAP filaments\", \"Mechanism coupling GFAP aggregation to ER/lysosome mispositioning not defined\", \"Writer PAT(s) for GFAP C291 palmitoylation not identified\", \"In vivo isoform-specific functions of GFAPα vs GFAPδ not established by genetic models\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 3, 14]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 1, 14]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [1, 16]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5, 6, 7, 21]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [3, 22]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [4, 10, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"S100B\",\n      \"CRYAB\",\n      \"VIM\",\n      \"PPT1\",\n      \"MECP2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"GFAP is the principal type III intermediate filament protein of astrocytes, serving as the structural backbone of the astrocyte cytoskeleton and a critical regulator of astrocyte–neuron interactions, cell morphology, and extracellular matrix adhesion. Its polymerization is directly inhibited by Ca²⁺-dependent S100 protein binding and modulated by alphaB-crystallin, while palmitoylation at Cys-291 (reversed by PPT1) regulates astrocyte proliferation and gliosis [PMID:7918670, PMID:19129171, PMID:33753498]. Transcription of GFAP is controlled by cooperative promoter elements (NFI, SP1, STAT3, NF-κB) and epigenetic mechanisms including DNA methylation, histone acetylation, and MeCP2 binding, and is induced by TGF-β1/Smad–MAPK/PI3K signaling downstream of glutamate [PMID:23832770, PMID:18419760, PMID:24269336, PMID:29852171]. Dominant missense mutations in GFAP cause Alexander disease through protein aggregation into Rosenthal fibers, impaired vesicle trafficking and ATP secretion, disrupted organelle distribution, and reduced proteasomal function [PMID:11138011, PMID:30355500, PMID:19146851].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing the first direct mechanism regulating GFAP filament dynamics: S100 protein was shown to inhibit GFAP polymerization in a Ca²⁺-dependent manner, identifying an assembly checkpoint responsive to intracellular calcium.\",\n      \"evidence\": \"In vitro sedimentation and viscometry polymerization assays with purified proteins\",\n      \"pmids\": [\"7918670\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the specific S100 family member(s) acting in vivo not resolved\", \"Whether other intermediate filament-associated proteins compete with S100 for GFAP binding is unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"GFAP was shown to be required for normal astrocyte–neuron communication: GFAP-null mice had severely reduced astrocyte intermediate filaments and enhanced hippocampal LTP, demonstrating that GFAP constrains synaptic plasticity.\",\n      \"evidence\": \"Gene-targeted knockout mouse with electrophysiological recording in hippocampal slices\",\n      \"pmids\": [\"8692820\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which GFAP loss enhances LTP (gliotransmitter release, K⁺ buffering, structural support) was not determined\", \"Whether other intermediate filaments (vimentin) partially compensate was not addressed\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Excess wild-type GFAP was shown to be sufficient to cause astrocyte pathology: transgenic GFAP-overexpressing mice formed Rosenthal fiber inclusions identical to those in Alexander disease and developed fatal encephalopathy, establishing a dose-dependent gain-of-function mechanism.\",\n      \"evidence\": \"Transgenic mouse overexpression with histological and immunohistochemical analysis\",\n      \"pmids\": [\"9466565\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Threshold of GFAP overexpression required to trigger pathology not quantified\", \"Whether Rosenthal fibers are directly toxic or markers of a broader proteostatic failure was unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"TGF-β1 was identified as a key transcriptional inducer of GFAP, counteracted by FGF-2 through tyrosine kinase signaling in a protein-synthesis-dependent manner, establishing growth factor cross-talk in GFAP regulation.\",\n      \"evidence\": \"Astrocyte culture with northern/western blot, pharmacological inhibition, cycloheximide chase\",\n      \"pmids\": [\"9537840\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the protein whose new synthesis is required for FGF-2-mediated repression was not established\", \"Whether this cross-talk operates in vivo during injury responses is untested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Dominant missense mutations in GFAP were identified as the cause of Alexander disease — the first Mendelian astrocyte disorder traced to a single gene — directly linking GFAP sequence variants to Rosenthal fiber formation.\",\n      \"evidence\": \"DNA sequencing of patient cohorts with cellular transfection validation\",\n      \"pmids\": [\"11138011\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How individual mutations alter GFAP filament assembly at the structural level was not resolved\", \"Genotype–phenotype correlations for severity and onset age were incomplete\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Expansion of the Alexander disease mutation catalog across infantile, juvenile, and adult forms confirmed a consistent gain-of-function mechanism for all pathogenic GFAP variants.\",\n      \"evidence\": \"Multi-center patient cohort sequencing with cellular transfection assays\",\n      \"pmids\": [\"15732097\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether different mutations activate distinct downstream stress pathways was not addressed\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The signaling cascade upstream of GFAP transcriptional induction was elaborated: glutamate activates the GFAP promoter through mGluR2/3-mediated TGF-β1 secretion, Smad-2 nuclear translocation, and cooperative MAPK/ERK and PI3K pathway engagement.\",\n      \"evidence\": \"GFAP-lacZ reporter astrocytes with neutralizing antibodies and pathway-specific pharmacological inhibitors\",\n      \"pmids\": [\"18419760\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Smad and MAPK/PI3K signals converge on the same promoter elements or act on distinct cis-elements not determined\", \"Contribution of this pathway relative to other injury signals in vivo is unknown\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Both excess wild-type and mutant GFAP were shown to impair proteasomal function and decrease cell proliferation in primary astrocytes, identifying proteostatic collapse as a central feature of GFAP toxicity in Alexander disease.\",\n      \"evidence\": \"Primary astrocyte cultures from transgenic and knock-in AxD mouse models with proteasome activity and cell death assays\",\n      \"pmids\": [\"19146851\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether proteasome impairment is a direct effect of GFAP aggregates or secondary to sequestration of proteasome regulators is unclear\", \"Relative contribution of impaired autophagy vs. proteasome dysfunction not dissected\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"alphaB-crystallin was established as an astrocyte-specific suppressor of GFAP toxicity: its genetic elevation rescued AxD mouse models from seizures and restored glutamate transporter expression, while its loss exacerbated mortality.\",\n      \"evidence\": \"Epistatic genetic crosses (GFAP-overexpressor × Cryab-null; AxD knock-in × Cryab-transgenic) with survival, IHC, and western blot\",\n      \"pmids\": [\"19129171\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of Cryab action (direct chaperone activity on GFAP filaments vs. aggregate clearance) not resolved\", \"Whether Cryab restoration is therapeutically viable in humans is untested\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Cooperative transcription factor architecture of the GFAP promoter was mapped in vivo: NFI, SP1, STAT3, and NF-κB sites each contribute to promoter strength and astrocyte specificity, with a cooperative B-region spanning four contiguous elements.\",\n      \"evidence\": \"Transgenic mice with block-mutant and site-specific mutant GFAP-reporter constructs\",\n      \"pmids\": [\"23832770\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which factor combinations are essential versus modulatory in different brain regions is not resolved\", \"Chromatin context and 3D promoter architecture were not examined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Epigenetic regulation of GFAP was demonstrated through MeCP2 binding to the methylated GFAP promoter; MeCP2 knockdown in vivo increased GFAP expression in a sex-specific manner, revealing a layer of epigenetic control.\",\n      \"evidence\": \"In vivo siRNA knockdown in neonatal rat amygdala and hypothalamus with RT-qPCR and western blot\",\n      \"pmids\": [\"24269336\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of the sex-specific effect is unknown\", \"Relationship to MeCP2 loss in Rett syndrome pathology not explored\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"GFAP isoforms (α and δ) were shown to exert distinct functions: GFAP-α knockdown altered integrin expression and cell motility, while pan-GFAP knockdown drastically increased laminin adhesion, demonstrating isoform-specific regulation of astrocyte–ECM interactions.\",\n      \"evidence\": \"shRNA-mediated isoform-specific knockdown with motility, adhesion, integrin, and ECM protein analysis in astrocytoma cells\",\n      \"pmids\": [\"24696300\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether these isoform-specific ECM effects operate in primary astrocytes and in vivo is untested\", \"Direct binding partners that distinguish the isoforms at the ECM interface are unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"FRAP experiments revealed that GFAPδ exchanges more slowly than GFAPα within the filament network and that GFAPδ-induced network collapse alters focal adhesion size, linking isoform dynamics to cytoskeletal mechanotransduction.\",\n      \"evidence\": \"Fluorescence recovery after photobleaching and focal adhesion analysis in astrocytoma cells\",\n      \"pmids\": [\"27141937\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether altered exchange kinetics are due to intrinsic assembly differences or differential partner interactions is unclear\", \"Relevance of GFAPδ network collapse to in vivo astrocyte morphology not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Alexander disease mutations in GFAP were shown in a human iPSC model to disrupt organelle distribution (ER and lysosomes perinuclear redistribution), impair ATP secretion, and attenuate calcium wave propagation, identifying vesicle trafficking and secretory function as primary cellular deficits.\",\n      \"evidence\": \"Patient-derived iPSC astrocytes with CRISPR/Cas9 isogenic correction, organelle imaging, ATP release assay, calcium imaging\",\n      \"pmids\": [\"30355500\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether organelle redistribution is a direct mechanical consequence of GFAP aggregation or mediated by motor protein dysfunction is unknown\", \"Contribution of impaired ATP release to non-cell-autonomous neuronal damage not quantified\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Thyroid hormone was shown to regulate GFAP expression through coordinated DNA methylation and histone acetylation at the GFAP promoter, with maternal hypothyroidism causing epigenetic silencing reversible by hormone supplementation.\",\n      \"evidence\": \"Rat hypothyroidism model with bisulfite sequencing, ChIP, HDAC activity assay, and hormone rescue\",\n      \"pmids\": [\"29852171\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Which DNA methyltransferases and HDACs are directly recruited to the GFAP promoter in this context is not identified\", \"Whether this contributes to neurodevelopmental deficits of congenital hypothyroidism is speculative\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Palmitoylation at Cys-291 was identified as a post-translational modification that regulates GFAP function: hyperpalmitoylation (as in PPT1 deficiency) promotes astrocyte proliferation and gliosis, while a C291A knock-in attenuates neurodegeneration, revealing a lipid modification switch on GFAP.\",\n      \"evidence\": \"Palm-proteomics, in vitro palmitoylation assay, C291A knock-in mouse, cell proliferation assay\",\n      \"pmids\": [\"33753498\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"The palmitoltransferase(s) that modify Cys-291 are not identified\", \"How palmitoylation alters GFAP filament assembly or protein–protein interactions at the molecular level is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key open questions remain: the structural basis by which individual Alexander disease mutations alter GFAP assembly, the identity of the palmitoltransferase modifying Cys-291, the mechanism linking GFAP aggregation to organelle redistribution and proteasome impairment, and whether alphaB-crystallin-based strategies can be translated therapeutically.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structural model of pathogenic GFAP filament assembly exists\", \"Causal chain from GFAP aggregation to proteasome impairment versus autophagy dysfunction not dissected\", \"Therapeutic window for Cryab or depalmitoylation strategies in Alexander disease unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 1, 6]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [6, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 1, 6, 7]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [0, 7, 19]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 13, 14]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [2, 3, 9, 10, 12]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [0, 19]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CRYAB\",\n      \"S100B\",\n      \"PPT1\",\n      \"VIM\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}